AFL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Aflac Inc (AFL) is not a strong buy for a beginner, long-term investor at this moment. While the company shows strong buyback performance and dividend growth, its recent financial performance has been weak, with significant drops in revenue, net income, and EPS. The technical indicators are neutral, and there are no strong trading signals from Intellectia Proprietary Trading Signals. Additionally, insider selling and a lack of recent congress trading data reduce confidence in the stock's immediate potential.
The MACD is below 0 and negatively contracting, RSI is neutral at 54.851, and moving averages are converging, indicating no clear trend. The stock is trading near its support level (S1: 111.529) but far from the pivot (114.295), suggesting limited upside potential in the short term.
Aflac has a strong history of share buybacks, repurchasing 38% of its shares over the past decade, which has boosted EPS and dividend growth. The company also strategically accelerates buybacks during price dips, demonstrating effective market timing. Additionally, automation of 54% of 'wellness' claims has improved operational efficiency.
Insider selling has increased significantly (528.02% over the last month), which could indicate a lack of confidence from within the company. Analysts' ratings are mixed, with some firms lowering price targets and expressing concerns about limited sales growth in key markets.
In Q4 2025, Aflac's revenue dropped to $4.87 billion (-9.94% YoY), net income fell to $1.38 billion (-27.50% YoY), and EPS decreased to $2.64 (-22.81% YoY). While gross margin remained flat, the overall financial performance indicates a challenging environment.
Analysts are mixed on Aflac. Recent price target changes include Wells Fargo raising the target to $118 with an Equal Weight rating, while TD Cowen and Barclays lowered their targets to $100 and $101, respectively, citing headwinds in the life insurance sector. BofA remains optimistic with a $120 target and a Buy rating, but concerns about limited sales growth and macroeconomic risks persist.
